BioCentury
ARTICLE | Clinical News

CHMP recommends Shire's Adynovi for hemophilia A

November 16, 2017 1:00 AM UTC

EMA's CHMP recommended approval of Adynovi (Adynovate - U.S., Japan; BAX 855) from Shire plc (LSE:SHP; NASDAQ:SHPG) to treat and prevent bleeding in hemophilia A patients ≥12 years of age. The pegylated form of recombinant Factor VIII is approved in the U.S. and Japan as Adynovate...

BCIQ Company Profiles

Shire plc